Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors (099)
Emily Hinchcliff(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Ying Yuan(The University of Texas MD Anderson Cancer Center), David M. Gershenson(The University of Texas MD Anderson Cancer Center), Aaron Shafer(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Patrick Hwu(Moffitt Cancer Center), Jason Roszik(The University of Texas MD Anderson Cancer Center), Pamela T. Soliman(The University of Texas MD Anderson Cancer Center), Jen Wargo(The University of Texas MD Anderson Cancer Center), David Vining(The University of Texas MD Anderson Cancer Center), Manoj Chelvanambi(The University of Texas MD Anderson Cancer Center), R. Tyler Hillman(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Michael Frumovitz(The University of Texas MD Anderson Cancer Center), Nicole D. Fleming(The University of Texas MD Anderson Cancer Center), Sanghoon Lee(Gyeongguk National University), Jinsong Liu(Guangzhou Institutes of Biomedicine and Health), Anil K. Sood(The University of Texas MD Anderson Cancer Center), Ami Patel(The University of Texas MD Anderson Cancer Center), Karen Lu(The University of Texas MD Anderson Cancer Center), Larissa A. Meyer, Dhakshina Moorthy Ganeshan(The University of Texas MD Anderson Cancer Center), Yan Liu(The University of Texas MD Anderson Cancer Center)
Cited by 6
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.5k
The Genomes of Oryza sativa: A History of Duplications
|PLoS Biology|2005|1k